
	Webcast of the press and analyst conference regarding the sale of the rights on Eligard^® to Astellas Pharma
	MediGene sells full European rights for Eligard® to Astellas for EUR 25 million and ongoing royalties more

	MediGene reports additional phase II results of EndoTAG(TM)-1 for the treatment of triple receptor-negative breast cancer more

	MediGene continues the global licensure of Veregen® through agreements with GC Rise in China and JS Bio Pharm in South Korea more

	MediGene AG reports on first quarter of 2010: total revenue increased – cost constant more

Drugs for the market

MediGene's vision is the expansion of the potentials in medicine
by means of utilizing biotechnology in a responsible manner.
We apply state-of-the-art technologies in the development of
innovative drugs for the treatment of cancer and autoimmune
diseases.